JPWO2021112220A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021112220A5 JPWO2021112220A5 JP2021562745A JP2021562745A JPWO2021112220A5 JP WO2021112220 A5 JPWO2021112220 A5 JP WO2021112220A5 JP 2021562745 A JP2021562745 A JP 2021562745A JP 2021562745 A JP2021562745 A JP 2021562745A JP WO2021112220 A5 JPWO2021112220 A5 JP WO2021112220A5
- Authority
- JP
- Japan
- Prior art keywords
- adrenomedullin
- peptide
- group
- agent according
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- ULCUCJFASIJEOE-NPECTJMMSA-N adrenomedullin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H]1C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)[C@@H](C)O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ULCUCJFASIJEOE-NPECTJMMSA-N 0.000 claims 14
- 102000004379 Adrenomedullin Human genes 0.000 claims 13
- 101800004616 Adrenomedullin Proteins 0.000 claims 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims 10
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 230000004048 modification Effects 0.000 claims 3
- 238000012986 modification Methods 0.000 claims 3
- 230000002159 abnormal effect Effects 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 235000018102 proteins Nutrition 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims 1
- 125000003827 glycol group Chemical group 0.000 claims 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019220695 | 2019-12-05 | ||
JP2019220695 | 2019-12-05 | ||
PCT/JP2020/045235 WO2021112220A1 (fr) | 2019-12-05 | 2020-12-04 | Agent thérapeutique pour maladie neurodégénérative avec accumulation anormale de protéines |
Publications (3)
Publication Number | Publication Date |
---|---|
JPWO2021112220A1 JPWO2021112220A1 (fr) | 2021-06-10 |
JPWO2021112220A5 true JPWO2021112220A5 (fr) | 2022-07-29 |
JP7498882B2 JP7498882B2 (ja) | 2024-06-13 |
Family
ID=76221768
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021562745A Active JP7498882B2 (ja) | 2019-12-05 | 2020-12-04 | 異常タンパク質蓄積性神経変性疾患の治療剤 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP7498882B2 (fr) |
WO (1) | WO2021112220A1 (fr) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009012571A1 (fr) * | 2007-07-20 | 2009-01-29 | Genesys Venture Inc. | Kallikréine tissulaire destinée au traitement de maladies associées à la protéine amyloïde |
JOP20190001B1 (ar) * | 2011-11-03 | 2022-03-14 | Bayer Pharma AG | عقار أولي معتمد على جليكول عديد إثيلين من أدرينومدالين واستخدامه |
US11414474B2 (en) * | 2014-03-20 | 2022-08-16 | University Of Miyazaki | Long-acting adrenomedullin derivatives |
SG10202008963QA (en) * | 2015-09-18 | 2020-10-29 | Univ Miyazaki | Long-acting adrenomedullin derivative |
-
2020
- 2020-12-04 JP JP2021562745A patent/JP7498882B2/ja active Active
- 2020-12-04 WO PCT/JP2020/045235 patent/WO2021112220A1/fr active Application Filing
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI72732B (fi) | Foerfarande foer framstaellning av nya, i 8-staellning aminosyraestergrupp innehaollande, angiotensin-ii-antagoniserande oktapeptidestrar. | |
AU2012326026B2 (en) | Peptidomimetic macrocyles | |
BR112014015156A2 (pt) | análogos de insulina à base de ctp, seus métodos de produção e uso no tratamento de hiperglicemia, bem como sequência de ácido nucleico e célula hospedeira | |
US20180371044A1 (en) | Peptidomimetic macrocycles | |
JP2020502051A5 (fr) | ||
WO2004020462A1 (fr) | Antagoniste de cxcr4 et son utilisation | |
BG65926B1 (bg) | Кахалалидни съединения | |
JP2011518179A5 (fr) | ||
JP2009532384A5 (fr) | ||
JPH06506699A (ja) | 抗血栓性ペプチドおよび偽ペプチド | |
JPH0753591A (ja) | 胃腸運動活性を抑制するモチリン類似ポリペプチド | |
JPWO2021112220A5 (fr) | ||
JP2019038772A5 (fr) | ||
AU684511B2 (en) | Oligopeptides derived from C-reactive protein fragments | |
JPH0770178A (ja) | 胃腸運動刺激活性を有するモチリン類似ポリペプチド | |
WO2022177878A1 (fr) | Antagonistes du récepteur du peptide-1 de type glucagon | |
AU2022222674A9 (en) | Glucagon-like peptide-1 receptor antagonists | |
JPWO2021112235A5 (fr) | ||
RU2760133C1 (ru) | Амиды гептапептида для лечения HMGB1-зависимых заболеваний | |
JPH08501066A (ja) | ペプチド化合物 | |
TW202245828A (zh) | 用於預防或治療肺部疾病的包括gip衍生物或其長效共軛物的藥學組成物 | |
EP0722459B1 (fr) | Penta/peptides ou hexapeptides hemoregulateurs | |
EP4230219A1 (fr) | Composition pharmaceutique comprenant un triple agoniste du glucagon/glp-1/gip ou un conjugué à action prolongée correspondant pour la prévention ou le traitement de maladies associées au lupus | |
US6342481B1 (en) | Oligopeptides derived from C-reactive protein fragments | |
JPH06509571A (ja) | タキキニン拮抗薬としての環状ヘキサペプチドの製法およびその薬学的化合物 |